|
|
Volumn 16, Issue SUPPL. 6, 2001, Pages 126-128
|
|
Lupus nephropathy in children
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINUCLEAR ANTIBODY;
AUTOANTIBODY;
CD40 ANTIGEN;
CHLORAMBUCIL;
COMPLEMENT COMPONENT C1Q;
COMPLEMENT COMPONENT C1R;
COMPLEMENT COMPONENT C2;
COMPLEMENT COMPONENT C4;
CORTICOSTEROID;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN;
CYTOKINE;
DNA ANTIBODY;
DOUBLE STRANDED DNA;
FC RECEPTOR;
HISTONE;
HLA A1 ANTIGEN;
HLA B8 ANTIGEN;
HLA DR3 ANTIGEN;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 10;
MYCOPHENOLIC ACID;
PHOSPHOLIPID ANTIBODY;
PREDNISONE;
PROTEIN BCL 2;
STEROID;
TACROLIMUS;
TUMOR NECROSIS FACTOR ALPHA;
ARTICLE;
CHILD;
CHILD CARE;
CHILDHOOD;
CLINICAL EXAMINATION;
CLINICAL FEATURE;
CLINICAL PROTOCOL;
CONTROLLED STUDY;
DISEASE CLASSIFICATION;
DISEASE PREDISPOSITION;
DISEASE SEVERITY;
HISTOPATHOLOGY;
HUMAN;
HUMAN TISSUE;
KIDNEY FAILURE;
LUPUS ERYTHEMATOSUS NEPHRITIS;
MAJOR CLINICAL STUDY;
PATHOGENESIS;
PLASMAPHERESIS;
PRIORITY JOURNAL;
PROGNOSIS;
RISK ASSESSMENT;
RISK FACTOR;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TREATMENT PLANNING;
|
|
EID: 0034797216
PISSN: 09310509
EISSN: None
Source Type: Journal
DOI: 10.1093/ndt/16.suppl_6.126 Document Type: Article |
|
Times cited : (24)
|
|
References (15)
|
